Broncho-Vaxom Adulti

Broncho-Vaxom is a well-known immunostimulant pharmaceutical product designed to prevent recurrent respiratory tract infections. It was originally developed in Switzerland by OM Pharma, a company specializing in the development of microbial-derived immunotherapeutic agents. The product contains a lyophilized bacterial lysate, which works by stimulating the body's natural immune defenses.

Manufacturing primarily takes place in Switzerland at OM Pharma's specialized facilities, ensuring high standards of pharmaceutical quality control. While OM Pharma was once part of the Vifor Pharma group, it returned to independence through an acquisition by Optum Health and private investors in 2020. As of 2024 and beyond, OM Pharma operates as a Swiss-based biopharmaceutical company with global distribution networks, maintaining its headquarters and primary operations in Meyrin, Switzerland.